- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01587131
DNA-based Influenza Vaccine in the Elderly
Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The use of DNA plasmids containing genes that express viral antigens may be a promising way to formulate a vaccine that can effectively prevent infection and disease caused by the H1N1 influenza virus. Plasmid vectors are simple to construct and are easy to manufacture at a relatively low cost. Vaccination with plasmids that express influenza proteins should induce the development of serum antibodies and might also induce significant quantities of secretory IgA antibodies and/or CMI. The DNA sequences included in the vaccine could also result in the proliferation of T lymphocytes that could broaden the effectiveness of the vaccine to include variant strains of H1N1 with antigenically modified HA (i.e., drifted strains).
Electroporation (EP) is a technology in which a transmembrane electrical field is applied to increase the permeability of cell membranes to create microscopic pathways (pores) and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. Their presence allows macromolecules, ions, and water to pass from one side of the membrane to the other. The presence of a constant field influences the kinetics of directional translocation of the macromolecular plasmid, such that the plasmid delivery in vivo has been sufficient to achieve physiological levels of secreted proteins. ID injection of a plasmid followed by EP has been used very successfully to deliver therapeutic genes that encode for a variety of hormones, cytokines, or enzymes in a variety of species. EP is currently being used in humans to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
The use of EP via the CELLECTRA® device should increase the expression of H1N1 influenza virus genes in the study vaccine.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
- MS Building Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent in accordance with institutional guidelines;
- Adults of either gender ≥ 65 years of age at entry;
- Healthy subjects, as judged by the Qualified Investigator based on medical history, physical examination, and normal results of an electrocardiogram (ECG), complete blood count (CBC), serum chemistries, and urinalysis done up to 4 weeks prior to enrollment and administration of vaccine or placebo by ID/EP;
- Current non-smoker (for 3 months prior to vaccine study);
- Willing to forego any other influenza vaccination during the study;
- Able and willing to comply with all study procedures.
Exclusion Criteria:
- Any concurrent condition requiring the continued use of systemic or topical steroids at or near the injection site (excluding inhaled and eye drop-containing corticosteroids) or the use of other immunosuppressive agents. All other corticosteroids must be discontinued ≥ 4 weeks prior to Day 1 of study vaccine administration;
- Administration of any blood product within 3 months of enrollment;
- Subjects with contraindications to influenza vaccination other than egg allergy (such as a history of Guillain-Barre Syndrome after receiving influenza vaccine);
- Administration of any vaccine within 6 weeks of enrollment; subjects may not receive any licensed seasonal influenza vaccine during the study unless they have been assigned to a study group receiving the seasonal vaccine;
- Participation in a study with an investigational compound or device within 4 weeks of signing informed consent;
- Subjects with cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);
- Subjects with a history of seizures (unless seizure free for 5 years);
- Subjects with tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination + EP;
- Subjects with any implanted heart leads;
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements;
- Prisoner subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study;
- Any other conditions judged by the investigator that would limit the evaluation of a subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group 1- DNA prime DNA boost
0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
|
0.9 mg FVH1 vaccine
|
EXPERIMENTAL: Group 2 - DNA prime Seasonal Vaccine boost
0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
|
0.9 mg FVH1 vaccine
|
PLACEBO_COMPARATOR: Group 3 - sWFI prime Seasonal Vaccine boost
100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
|
0.9 mg FVH1 vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of a DNA-based influenza vaccine composed of a combination of two different H1 HA plasmids administered ID followed by electroporation in healthy elderly adult subjects
Time Frame: Day 0 through Month 12
|
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
|
Day 0 through Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral and cellular immune responses
Time Frame: Day 0 through Month 12
|
Magnitude and frequency of antibody and cell mediated immune response to influenza proteins
|
Day 0 through Month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gary Kobinger, PhD, National Microbiology & University of Manitoba
- Study Director: Trina Racine, PhD, National Microbiology Laboratory, Canada
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2011:131
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on RNA Virus Infections
-
University of California, Los AngelesNational Institute on Aging (NIA)Enrolling by invitationVirus Infection, RNAUnited States
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus ImmunizationPuerto Rico, United States, Australia, Honduras, Mexico
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingRespiratory Syncytial Virus InfectionsUnited States, Finland, Ghana, Honduras, India, Spain, Thailand
-
Daiichi Sankyo Co., Ltd.CompletedRespiratory Syncytial Virus InfectionsJapan
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthCompletedVirus Diseases | ParainfluenzaUnited States
-
Daiichi SankyoCompleted
-
Shanghai Ark Biopharmaceutical Co., Ltd.Shanghai Ark Biopharmaceutical Co., Ltd.CompletedRespiratory Syncytial Virus InfectionsChina
-
Janssen Vaccines & Prevention B.V.Completed
-
Auro Vaccines LLCPATH; Coalition for Epidemic Preparedness Innovations; Cincinnati Children's...Completed
-
Montreal Heart InstituteNational Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation and other collaboratorsTerminatedCorona Virus InfectionSpain, United States, Canada, Brazil, Greece, South Africa
Clinical Trials on FVH1 - a DNA-based influenza vaccine
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedHematologic Malignancy | Hematopoietic Stem Cell TransplantUnited States
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
Shanghai Institute Of Biological ProductsCompleted
-
Jiangsu Province Centers for Disease Control and...Jiangsu Jindike Biotechnology Co., Ltd.Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Washington University School of MedicineCompleted